Comparison of integral doses to normal tissue and organs at risk between interstitial
high-dose-rate brachytherapy and modern external-beam radiotherapy techniques in breast
and head and neck cancer patients.
(Tématerületi Kiválósági Program 2021 (TKP2021-EGA-44))
Although a cornerstone of modern cancer treatment, radiotherapy (RT) is associated
with a risk of secondary cancer due to irradiation of non-target tissues. Techniques
such as intensity-modulated RT (IMRT), volumetric modulated RT (VMAT), and stereotactic
body RT (SBRT) provide highly conformal target dose distributions and reduce doses
to nearby organs at risk (OARs), albeit at the cost of larger normal tissue volumes
being irradiated with lower doses. In brachytherapy (BT), the low-value isodoses cannot
be changed: they are a consequence of the inverse-square law. This study evaluates
and compares the normal tissue integral doses (NTIDs) delivered by BT and modern external-beam
RT (EBRT) techniques in breast and head and neck (H&N) cancer patients.Included were
the BT and IMRT plans of 34 women with early-stage breast cancer treated with interstitial
high-dose-rate (HDR) BT and two groups of head and neck (H&N) patients: 38 patients
with mobile tongue, floor of the mouth, and base of the tongue cancer treated definitively
with interstitial HDR BT for whom VMAT treatment plans were also prepared and 20 patients
with tongue and floor of the mouth tumors who received postoperative interstitial
HDR BT for whom VMAT and stereotactic CyberKnife (CK, Accuray Inc., Sunnyvale, CA,
USA) plans were also created. The NTIDs for three normal tissue volumes (NT_V10, NT_V5,
NT_V2) and OARs were calculated and compared.Brachytherapy resulted in 39%, 32%, and
26% lower NTIDs compared to IMRT for NT_V10, NT_V5, and NT_V2, respectively, in patients
with breast cancer. In H&N cancer, the NTIDs were always lower for BT compared to
VMAT. The reductions in NTID achieved with BT were 45%, 36% and 27% with the same
planning target volumes in BT and VMAT, and 56%, 48% and 37% with larger planning
target volumes in VMAT. For CK, the NTID reductions were 54%, 49% and 41% compared
to BT. In breast cases, BT resulted in a significant reduction in ipsilateral lung
NTID, and in H&N cases, salivary glands NTIDs were always lower with BT than with
VMAT.For patients with breast and head and neck cancer, interstitial BT results in
lower integral dose to normal tissue and OARs compared to modern EBRT techniques.
The clinical implications require further detailed investigation.